Tofacitinib for Prurigo Nodularis: A Case Report

Abstract

Changlan Peng,1 Chunxiao Li,2 Yingying Zhou,1 Qiuyue Wang,1 Ping Xie,1 Tianhao Li,2,* Pingsheng Hao2,* 1Department of Dermatology, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tianhao Li; Pingsheng Hao, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, Sichuan Province, People’s Republic of China, Tel [phone], Fax [phone], Email [email protected]; [email protected]: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored.Patients and Methods: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects.Results: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis.Conclusion: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.Keywords: prurigo nodularis, JAK inhibitors, tofacitinib

Keywords

• prurigo nodularis
• jak inhibitors
• tofacitinib.